We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Provention Bio Inc | NASDAQ:PRVB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.98 | 25.04 | 24.90 | 0 | 01:00:00 |
From Jul 2021 to Jul 2024
By Stephen Nakrosis
Shares of biopharmaceutical company Provention Bio Inc. are higher in Thursday's late-trading session, after the company said it intends to resubmit the teplizumab Biologics License Application, following a meeting with the U.S. Food and Drug Administration.
The company said teplizumab is being developed to delay clinical type 1 diabetes in at-risk individuals.
"We look forward to re-submitting the BLA as soon as possible and facilitating the FDA's review and decision-making," said Ashleigh Palmer, co-founder and chief executive.
At 5:08 p.m. ET, shares were trading 12.65% higher at $3.83.
The stock finished the day's regular-trading session at a 52-week low of $3.40.
The company scheduled a conference for Jan. 28 at 8 a.m. ET.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 27, 2022 17:38 ET (22:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Provention Bio Chart |
1 Month Provention Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
